The expanded BXD family of mice: A cohort for experimental systems

genetics and precision medicine

David G. Ashbrook^{1,†,*}, Danny Arends^{2,*}, Pjotr Prins¹, Megan K. Mulligan¹, Suheeta Roy¹, Evan G. Williams³, Cathleen M. Lutz⁴, Alicia Valenzuela⁴, Casey J. Bohl¹, Jesse F. Ingels¹, Melinda S. McCarty¹, Arthur G. Centeno¹, Reinmar Hager⁵, Johan Auwerx⁶, Saunak Sen⁷, Lu Lu^{1,†}, Robert W. Williams^{1,†}

¹Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA

²Lebenswissenschaftliche Fakultät, Albrecht Daniel Thaer-Institut, Humboldt-Universität zu Berlin, Invalidenstraße 42, 10115 Berlin, Germany

³Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland

⁴Mouse Repository and the Rare and Orphan Disease Center, The Jackson Laboratory, Bar Harbor, ME USA 04609

⁵Division of Evolution & Genomic Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK

⁶Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland

⁷Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA

* Contributed equally to this work, and should both be considered as joint first authors.

[†] Corresponding authors: David G. Ashbrook, email: dashbrook@uthsc.edu; Robert W. Williams, email: rwilliams@uthsc.edu; Lu Lu, email: lulu@uthsc.edu

Author email & ORCID

David G. Ashbrook - dashbrook@uthsc.edu - 0000-0002-7397-8910

Danny Arends - danny.arends@gmail.com - 0000-0001-8738-0162

Pjotr Prins - jprins@uthsc.edu - 0000-0002-8021-9162

Megan K. Mulligan - mkmulligan@uthsc.edu - 0000-0003-4909-635X

Suheeta Roy - sroy12@uthsc.edu - 0000-0002-5996-6905

Evan G. Williams - williams@imsb.biol.ethz.ch - 0000-0002-9746-376X

Cathleen M. Lutz - cat.lutz@jax.org

Alicia Valenzuela - acv@jax.org

Casey J. Bohl - cbohl1@uthsc.edu

Jesse F. Ingels - jingels@uthsc.edu

Melinda McCarty - mmccarty@uthsc.edu

Arthur G. Centeno - acenteno@uthsc.edu - 0000-0003-3142-2081

Reinmar Hager - reinmar.hager@manchester.ac.uk - 0000-0002-6692-5669

Johan Auwerx - admin.auwerx@epfl.ch - 0000-0002-5065-5393

Saunak Sen - sen@uthsc.edu - 0000-0003-4519-6361

Lu Lu - lulu@uthsc.edu - 0000-0002-6174-3209

Robert W. Williams - rwilliams@uthsc.edu - 0000-0001-8924-4447

Abstract

The challenge of precision medicine is to model complex interactions among DNA variants, sets of phenotypes, and complex environmental factors and confounders.

We have expanded the BXD family, creating a powerful and extensible test bed for experimental precision medicine and an ideal cohort to study gene-by-environmental interactions.

These BXD segregate for over 6 million variants, with a mean minor allele frequency close to 0.5. We have increased the family two-fold to 150 inbred strains, all derived from C57BL/6J and DBA/2J. We have also generated updated and comprehensive genotypes and an unrivaled deep phenome.

Approximately 10,000 recombinations have been located, allowing precision of quantitative trait loci mapping of ± 2.0 Mb over much of the genome and ± 0.5 Mb for Mendelian loci. The BXD phenome includes more than 100 'omics data sets and >7000 quantitative and clinical phenotypes, all of which is publicly available.

The BXD family is an enduring, collaborative, and replicable resource to test causal and mechanistic links between genomes and phenomes at many stages and under a wide variety of treatments and interventions.

Keywords

Systems genetics, QTL, mapping resolution, power calculation, PheWAS, experimental precision medicine, recombinant inbred strain, mouse

Background

The origin of the BXD family

Recombinant inbred strains of mice, and the BXD family in particular, have been used for 45 years to map Mendelian and quantitative trait loci ^{1–5}. Production was started in 1971 by Benjamin A. Taylor by crossing a female C57BL/6J (B6 or B) and a male DBA/2J (D2 or D)—hence BXD. The first set of 26 (expanded in the 1990s to 35) recombinant inbred strains were intended mainly for mapping Mendelian loci ^{1,6}, but the family was soon used to map more complex quantitative traits—cancer susceptibility ^{7–9}, neuroanatomical traits ^{10–13}, and behavioral differences ^{14,15}, and pharmacological responses to toxicants and drugs ^{16–19}. All of these strains are still available from The Jackson Laboratory (JAX) and carry the strain suffix "/TyJ".

Production of BXD43 through BXD102 started in the late 1990s at the University of Tennessee Health Science Center (UTHSC) ^{20,21}. These new strains were derived from advanced intercross (AI) progeny that had been bred for as many as 14 generations before inbreeding ²² (Figure 1; Supplementary figure 1; Supplementary table 1). AI-derived BXDs incorporate roughly twice as many fixed cross-over events (recombinations) between *B* and *D* parental genomes compared to F2-derived BXDs—80 versus 40 ^{22–26} (Figure 2). This improved both power and precision.

Figure 1: Production of the BXD recombinant inbred family by either standard F2 (A) or advanced intercross (B). Four epochs of the BXD were derived from F2 (totaling ~75 strains) and two epochs were derived from advanced intercross (totaling ~65 strains). Red coloring has been used to represent regions of the genome coming from the inbred C57BL/6J (B6) parental strain, whereas white coloring has been used to represent regions of the genome coming from the inbred DBA/2J (D2) strain. Solid lines have been used to represent a single generation, whereas dashed lines represent several generations, with the number of generations written along the line. Full details can be found in Supplementary table 1 and Supplementary figure 1. Adapted from (Nadeau and Auwerx, 2019; Peirce et al., 2004; Williams and Auwerx, 2015)

Figure 2: Genome wide visualization of recombinations in the BXD family. For each chromosome we computed the number of observed recombinations per strain since the start of the chromosome (nRecS), ignoring the heterozygous and unknown genotypes. The number of recombinations for each BXD strains per chromosome was plotted using a color gradient. Strain numbers are used for the ordering on the X-axis, horizontal lines separate the different epochs, and these epochs are annotated on the X-axis. The mean number of inbreeding generations is shown each epoch. Full details of the epochs can be found in Supplementary figure 1 and Supplementary table 1. Note epoch 6 appears to have fewer recombinations due to a large number of heterozygous loci at the time of genotyping.

The expanded BXD family

Here we report on the production of new sets of BXD strains that double the family size to a total of 150 inbred stains. All have been genotyped using high-density SNP arrays. We have assembled genetic maps that improve power and mapping precision. What sets the expanded BXD family apart from all other resources for systems genetics is an unrivalled, dense and well-integrated phenome, of over 7000 classical phenotypes and over 100 'omics datasets. This open and publicly available phenome extends back to Taylor's 1973 analysis of cadmium toxicity through to recent quantitative studies of metabolism^{3,4,27,28}, addiction^{29–31}, behavior^{32–35}, the complex genetics of infectious disease^{36,37}, and even indirect genetic effects^{38–40}. The BXDs have been used to test specific developmental and evolutionary hypotheses^{10,41,42}, to study gene-by-environmental interactions (GXE), and to quantify the consequences of interventions and treatments as a function of genome, age, and sex⁵. We have also assembled deep and extensive 'omics resources, including full sequence for both parents^{3,27,37,43,44}, access to almost all BXD expression and phenotype data freely available on open source web services, and powerful statistical tools designed for global analysis (e.g. GeneNetwork.org and Systems-Genetics.org)^{5,45,46}. Use of the expanded BXDs has accelerated. There are currently more than 500 BXD-related publications, of which more than 100 were published in the last five years.

Compared to conventional F2 and advanced intercrosses (AIs), outcrossed heterogenous stock, or diversity outbred stock, the BXD are particularly advantageous when the heritability of a trait is moderate or low because genetic signal can be boosted

greatly by resampling isogenic members of the same line many times⁴⁷. The main benefit however is that those using BXDs gain access to coherent genomes and quantitative phenomes generated under diverse laboratory and environmental conditions⁴⁸. New data can be compared to thousands of publicly available quantitative traits, and with each addition, the number of network connections grows quadratically—enabling powerful multi-systems analysis for all users.

Genetic research is moving toward predictive modeling of mechanisms, health status and disease risk, and the efficacy of interventions⁴⁹. The expanded BXD family is extremely well suited to address more integrative questions that encompass both high levels of genetic and environmental variation. The family is also extendible into a massive diallel cross (DX) made up of 23,104 (152^2) isogenic lines, all of which have an entirely defined genome, and any subset of which can be generated efficiently for *in vitro* and *in vivo* predictive biology and experimental precision medicine.

Results

The current phase of BXD production

We initiated 108 new strains between 2009 and 2013 (BXD104–BXD220). Of these, 49 are now at filial generation 20 (F20) or higher. Inbreeding depression is a serious problem. Of 108 strains we initiated in this most recent phase of the BXD expansion, 44 are either extinct or required out crossing to save (Supplementary figure 1, Supplementary table 1). We are now testing a simple alternative in which struggling pairs of nearly inbred strains

are crossed to produce more viable F1 progeny that are then used to initiate a new inbred line ^{23,50,51} (Supplementary figure 1).

As of March 2019, a total of 121 BXD lines are available from The Jackson Laboratory, 98 of which are listed as 'Repository Live' (a lead time of 0–2 weeks), 15 are listed as on pre-order (currently in production), and 8 are cryopreserved (Supplementary table 1). An additional 29 incipient BXD strains are available from the group at UTHSC, and will be donated to JAX once they are fully inbred. All BXDs are available under a standard material transfer agreement; the most important limitation being that strains cannot be sold or distributed without approval of The Jackson Laboratory or UTHSC.

Errors during production

We have identified strains with markedly similar genotypes resulting from production errors, where a mismatched strain was crossed during production or maintenance, and these now related sets of strains have been renamed and marked by the addition of "a" and "b" suffixes. For example, BXD65, BXD65a (originally BXD97), and BXD65b (originally BXD92) are identical by descent across 90% or more of their genomes. There are important statistical consequences of non-independence and admixture of this type. For example, without corrections, the inclusion of these three BXD65 substrains gives them undue influence over results (but can be highly interesting if differences are seen between them). These production errors are different from the expected and much more subtle relations among all BXD family members that results from the inevitable pedigree relatedness (identity by descent), and by genetic drift, backcrossing, and unintended

selection. Fortunately, correcting for both types of non-independence is no longer difficult using advanced QTL mapping algorithms. The Genome-wide Efficient Mixed Model Association (GEMMA) algorithm (github.com/genetics-statistics/GEMMA) has been implemented in GeneNetwork2⁴⁶ and performs kinship correction during mapping.

Improved genetic mapping

Approximately 198 BXD strains have been genotyped at over 100,000 informative markers using Affymetrix and Illumina array-based platforms^{6,20,52,53}. Most markers, even those that are nominally informative, provide redundant information. Until 2016, a subset of 3,830 markers were used for mapping of phenotypes in BXD1 to BXD102. In this study we have increased the number of useful markers to 7,324. This set of markers either have unique genotype patterns (also known as “strain distribution patterns”) or define the proximal or distal limits of chromosomal intervals that are non-recombinant (plateau regions). Markers are spaced at an average of 0.63 Mb $\pm$ 1.0 SE, closely matching the asymptotic map resolution of $\pm$ 1 Mb. There are still ~200 gaps of 2 Mb or greater without informative markers. In all cases these regions are almost identical by descent between parental strains. Five of the largest gaps are on Chr X (from 8 to 25 Mb), and other gaps are on Chrs 7, 8, 9, 14 and 18.

Moving from 3830 to 7324 markers has significantly improved the ability to detect significant linkage. For instance, Figure 3 contrast maps for *Ectromelia* virus-induced mortality (GeneNetwork trait 10043) mapped using either the older and smaller set of markers (Figure 3A) or the newer and larger set of markers (Figure 3B). A previously non-

significant QTL for this trait originally published in 1991⁵⁴ now achieves genome-wide significance.

Figure 3: Improved mapping using updated marker map on identical data. QTL maps for GeneNetwork phenotype 10043, *Ectromelia* virus-induced mortality in BXD males, mapped using either the ‘classic’ (2001–2016) genotypes (A), or the ‘new’ (2017+) genotypes (B). The blue line represents the genome scan, showing the likelihood ratio statistic (LRS) associated with each marker across the 19 autosomal and the X chromosome. The top, pink, line marks genome-wide significance, the lower, grey, line the suggestive significance threshold. The green or red lines show the additive effect coefficient, with green showing that *D* alleles increase trait values and red that *B* alleles increase trait values. The green axis on the right shows by how much the alleles increase trait values.

To quantify the improvement in mapping, we computed linkage for the entire BXD phenome (7562 phenotypes), using three different genotype files. We used the classic (2001–2016) and new genotypes (used since 2017), as well as the original BXD reference genotypes (pre-2001). Each update approximately doubles the number of markers (from 1566, to 3830, and now 7324). We counted numbers of phenotypes with likelihood ratio

statistic (LRS) scores at three cut-offs: 15 (suggestive), 20 (significant) and 25 (highly significant) (Table 1). The new genotype files increase the number of QTLs detected at suggestive and significant LRS levels, increasing the percentage detected by 17–19% and 24–26% respectively. However, there is a much smaller increase (2% and 10% respectively) at the highly significant cutoff (LRS >25) because large effect QTLs and Mendelian loci are relatively insensitive to low marker density.

Table 1: Increase in power to detect QTL using genotype files with increasing numbers of markers. For each of three genotype files with increasing numbers of markers (original = 1566 markers; classic = 3830; current = 7324) the number of phenotypes with an LRS value greater than the three threshold values (15, 20 and 25) is shown. For the classic and current genotype files, the percentage increase from the 'original' genotype file is also shown.				
		Genotype files		
		'original'	'classic'	'current'
LRS threshold	15	1630	1911 (17.2%)	2049 (25.7%)
	20	421	499 (18.5%)	524 (24.5%)
	25	168	171 (1.8%)	185 (10.1%)

Empirical mapping precision ranges from 0.25 to 5 Mb

We computed the empirical precision of mapping using a total of ~270,000 *cis*-acting expression QTLs (eQTLs) with logarithm of odds (LOD $\approx -\log P \approx \text{LRS}/4.61$) scores greater than 3.0 and within ± 10 Mb of the cognate gene (Figure 4). This definition of a *cis*-acting eQTL is conservative in the sense that our 20 Mb acceptance window will degrade empirical estimates of precision because hits will include some regional *trans*-acting eQTLs. However, we view this approach as necessary to guard against overly optimistic estimates of precision.

The mean precision for 17,805 eQTLs with LOD scores above 10 is ± 0.96 Mb using transcriptome datasets containing only 60–80 BXDs. The median precision is 0.52 Mb. In

other words, the offset between the location of the gene (using the more proximal end as a reference point), and the location of the SNP with the highest LOD score across the entire genome is generally less than 1 Mb. There is naturally high regional variation in precision (Figure 4). Most of the intervals with low precision are associated with intervals in which we have not yet defined locations of all recombinations, a problem that is now being solved by new sequence-based infinite marker maps ⁵⁵. There may also be problematic regions of BXD genomes that contain large structural variants (duplication, inversions, etc) compared to the reference genome.

It is possible to achieve subcentimorgan mapping precision with the BXD family, using only half of the full set of BXDs (Figure 4). Once genotypes are perfected by full genome sequencing we expect that with 60–100 strains users will achieve a mean resolution of 500 Kb and a median resolution of 250 Kb for Mendelian loci. Three factors contribute to this surprising precision: 1. the well balanced distribution of parental alleles across the genome (minor allele frequencies close to 0.5); 2. the ability to boost the effective trait heritability by resampling ⁴⁷; and 3. the comparatively high density of recombinations archived in 150 BXDs thanks in part to the use of AI-derived strains (Figure 2). This level of precision does not differ appreciably from that typical of the Collaborative Cross, the Diversity Outbred, or even highly recombinant HS stock. In any case, precision much finer than this will often not be critical. The fuzzy functional boundaries of genes and the often high density of variants in linkage with each other shifts the burden of proof from pure mapping strategies to functional genomics, comparative analysis of human

cohorts, complementary animal models, and to direct pharmacological and genetic engineering⁵⁶.

The power of mapping with the BXD family

An analysis of statistical power is useful to estimate numbers of replicates and strains needed to detect and resolve major sources of trait variance and covariance. To start with the conclusion—it is almost always better to study small numbers of as many strains as can be obtained given the logistics of breeding, transportation, and experimental design^{2,47}. Studying as few as two to four of each of 100 or more strains may strike many as counterintuitive but this is the right approach even for traits with low heritability. This fact has been the single most important motivation for increasing the number of BXD strains^{2,47}.

In the context of mapping traits, an effective sample size can be estimated using

an equation developed in Belknap and colleagues (1996). A more versatile method has been developed by Sen and colleagues⁵⁷ and implemented in the R package *qtlDesign* based on the H^2_{RIX} ⁴⁷. This heritability of strain means, in contrast to the heritability for individuals, is defined as $H^2_{RIX} = V_a/(V_a + V_e/n)$, where V_a is the genetic variability (variability between strains), V_e is the environmental variability (variability within strains), and n is the number of within line replicates. This equation highlights the usefulness of isogenic cohorts such as the BXD: the same genomotype can be sampled multiple times, increasing the effective heritability. We rename this H^2_{RIX} to H^2_{IX} because it applies to all isogenic strains, not just recombinant inbred strains, for example diallel crosses (DXs, also known as RI intercrosses; RIXs)^{58,59} or hybrid diversity panels of inbred strains.

Given an estimated heritability and effect size, what is the optimum number of strains and number of biological replicates to use, given the need to maximize power and minimize the number of animals being used? To answer this, we have developed a power app to allow the user to examine these interactions in a two-founder recombinant inbred population, such as the BXD (https://dashbrook1.shinyapps.io/bxd_power_calculator_app/). This tool provides a clear visual demonstration that when heritability is low to intermediate, the gain in power from increasing the number of replicates is significant up to about four replicates and then tails off rapidly when heritability is higher than 0.5. Unsurprisingly, at heritabilities greater than 0.5 power is high even with as few as two replicates (Figure 5).

Investigators have to decide on the most effective use of limited resources, and this means decisions have to be made regarding the optimal design in terms of numbers of replicates and number of lines ⁵. For example, when limited to phenotyping 200 animals, the investigator must choose between phenotyping 10 lines with 20 replicates or phenotyping 40 lines with 5 replicates (reviewed in Williams and Williams, 2017). The figure and table in the power app reveals that for all levels of heritability it is always better to maximize the number of genomes rather than the number of replicates. Thus, even when heritability is low, increasing the number of replicates when more lines are available will not increase power to the same degree as increasing the number of lines. However, phenotyping more replicates will yield more reliable within-genotype variation estimates. Therefore, when using the expanded BXD panel we recommend phenotyping three to six replicates per line, when possible, using a balanced number of males and females. This is also optimal from a logistical standpoint, since it is often easier to obtain small numbers of animals for many strains from the Jackson Laboratory and other breeding centers. There is one exception to this advice. If one intends to select extreme response or outlier genomes for detailed analysis, then it is advisable to perform more extensive replication of these exceptionally interesting strains. In this context it should be noted that in samples with a small number of strains, the effect sizes of loci tend to be severely overestimated ^{60,61}. The utility and efficiency of RI and DX cohorts relative to F2 and heterogeneous stock cohorts is improved when heritability is low and numbers of replicates within strain are minimized (see Figure 3 from ⁴⁷).

Other factors to consider are genotyping costs, the resolution of genetic maps, and easy access to phenome data.

Figure 5: The relations between power, number of strains and within-strain replicates in recombinant inbred strains generated using qtlDesign (Sen et al., 2007). **A:** Power to detect a given effect for different numbers of replicates and different numbers of strains. Allele effect size and heritability were kept constant at 0.5. This shows that more replicates increase power but beyond four replicates the gain in power is marginal. At very low effect sizes power is low anyway, and then increases for intermediate levels. However, with large effect sizes, beyond 2 replicates very little power is gained. **B:** Effect size detectable, given different numbers of replicates and strains. Heritability was kept at 0.5, power was kept at 0.8. **C:** Power to detect a given effect size, dependent upon heritability and number of biological replicates. Allele effect size was kept at 0.8; number of BXD strains was kept at 40. The figure illustrates that with very low H^2 there is no power, and that with lower H^2 the gain in power is stronger with increasing number of replicates compared with high H^2 ; again, beyond four replicates, the gain in power is marginal. **D:** Power to detect a given effect size, dependent upon heritability, with a total of 200 animals. These range from 200 lines with 1 replicate to 10 lines with 20 replicates. The figure shows that in contrast to what one might assume, even for low levels of H^2 , power always increases with more lines rather than more replicates. Effect size was kept at 0.8.

Discussion

Kinship relations and genetic drift

The expanded family of BXDs is a powerful resource for both forward and reverse genetic analysis of genome-to-phenome linkage. As this family has grown in size, relations among individual strains have become complex. Mapping algorithms that do not account for kinship (e.g. Haley-Knott methods) are no longer appropriate. We find it almost essential to use linear mixed models ^{62–64} or nonparametric equivalents such as a mixed random forests ⁶⁵ that account for kinship, epoch, and other cofactors. Several of these methods are now accessible in GeneNetwork 2 ⁴⁶ and R/qtI2 ⁶⁶.

The BXDs have kinship at several levels. First, there is random fixation and selection during the process of inbreeding ²³. Second, there are notable differences in kinship among AI-derived strains, including BXD43 to BXD102 and BXD160 to BXD186 ²⁰. This kinship has its origins mainly in the 8–14 generations of intercrossing that preceded inbreeding ²². Third, there are substrain groups highlighted by common numbers but unique substrain codes (e.g. BXD24/TyJ, BXD24/Tyj-Cep290<rd16>/J, BXD29/TyJ and BXD29-Tlr4<lps-2J>/J). Both pairs are co-isogenic, and carry unique spontaneous mutations. In contrast, the set closely related BXD48s; BXD65s, and BXD73s resulted from production errors. Fourth, there is kinship based on epochs. Each epoch of BXDs were generated with unique B6 and D2 parents, albeit nominally the same strains. These parents, but more importantly their progeny BXD strains, differ due to fixation of spontaneous mutations inherited from both parents. Finally, each strain will fix a variable

number of rare spontaneous mutations during inbreeding. While these rare fixed mutations do not produce an epoch effect, they can produce remarkable outlier strains.

Shifman and colleagues⁶⁷ detected a surprisingly large number of new variants ($n = 47$ out of about 13,000 SNPs) in the set of strains generated by Taylor in the early 1990s (BXD33 though BXD42), and a small number ($n = 5$) of even more recent mutations in BXDs generated in the late 1990s at UTHSC. While the majority of mutations are neutral or non-functional, we already know that a handful produce interesting differences in gene expression and higher order phenotypes among different phases of the BXD family^{68,69}. Analysis of expression data from different epochs highlights ~50 genes modulated by strong cis-acting expression QTLs only in newer strains. For example, introduction of a premature stop codon in glycoprotein nmb (*Gpnmb*) and deletion of the last coding exon in killer cell lectin like receptor D1 (*Klrd1*; CD94) occurred spontaneously in the DBA/2J paternal strain in the 1980s^{70,71}. The result is a loss of function through truncation of each protein and both genes are associated with strong cis eQTLs, but only in the newer strains. The same phenomenon is true of spontaneous mutations that occurred in the 1980s in the C57BL/6J maternal parent that led to the deletion of *Nnt* exons and a striking reduction in *Gabra2* expression in brain^{68,72,73}.

Improved mapping of BXD phenome and omics data

The BXD were first used to map trait variants segregating in the parental strains in the early 1970s. Even with sparse genotypes, Taylor and colleagues were able to map a cadmium toxicity locus to a 24 cM interval¹. We compared the pre-2001 'original', 2001-

2016 ‘classic’, and post-2017 ‘current’ genotype files. The latest file increases the number of QTLs detected at a LRS threshold of 20 by ~25%. As a specific example, using the latest genotypes and the GEMMA mapping algorithm, Taylor’s 1970s data (BXD Phenotype 13035) now gives a map with a 2-LOD confidence interval of 3 Mb. When this map is combined with SNP data for 29 common strains that Taylor and colleagues also generated in their landmark study (GN 49785 in the Mouse Diversity Panel cohort) this locus can be restricted to a 400 Kb region centered at SNP rs13477430 that includes *Slc39a8*, a heavy metal transporter expressed almost exclusively in the testes. This locus was formally cloned by Dalton and colleagues in 2005, although the causal variant has still not been defined functionally ⁷⁴.

This highlights two important points. First, it is possible to map Mendelian traits and even quantitative traits with modest LOD scores with good precision, even when using a small numbers of strains ^{75–77}. Second, a good way to transition from QTLs to specific genes, variants, and mechanisms is often to use complementary resources such as panels of common inbred strains, Collaborative Cross (CC), or Diversity Outbred (DO) cases, efficient screens of candidate genes using *in vitro* and *in vivo* assays ^{48,76}, and even human genome-wide association study (GWAS) data ^{78–82}. But the most obvious way to improve precision and power is to simply use a larger numbers of strains.

Cloning QTLs and quantitative trait (QT) nucleotides is becoming significantly easier thanks to this excellent precision, improved genotypes ^{23,67,83,84}, full genome sequence for both parental strains ^{3,43}, powerful omics resources for the BXDs ^{4,27,85,86}, better mapping algorithms that account for cofactors and admixture ^{62,87,88}, and far more

efficient molecular validation methods ⁴⁵. The BXDs have been used to clone roughly 20 QTLs, including two tightly linked genes, *ligp2* and *Irgb10*, for *Chlamydia* infectivity ^{89,90}, *Fmn2* as a master controller of tRNA synthetases in neurons ⁹¹, *Ubp1* for blood pressure ⁷⁸, *Hc* for H5N1 influenza resistance ⁹², *Comt* as a master controller of neuropharmacological traits ⁹³, *Alpl* for hypophosphatasia ², *Mrps5* for longevity ⁷⁶, *Bckdhb* for maple syrup urine disease, *Dhtkd1* for diabetes ²⁷, *Hp1bp3* for cognitive aging ⁹⁴, and *Ahr* for locomotor activity ⁹⁵.

The BXD phenome is unrivalled for experimental precision medicine

The BXDs are currently the largest and most deeply phenotyped vertebrate genetic reference panel, and have been used by well over 200 groups worldwide. Researchers benefit from access to an expanded BXD family, which has been increased by 88 strains to a total of 150 extant strains ⁴¹. Almost all of the data are freely accessible at GeneNetwork (<https://gn2.genenetwork.org/>) ^{46,87,96}. The assembly of phenome data and their integration into a web service was started in 2001 ^{21,97} and is still a core activity of our groups ³. This wealth of legacy data accumulated over the past four decades is represented by well over 1,000 publications, over 7,000 open phenotypic measurements, 150 open genome-wide molecular profiles that include proteome data sets generated under different metabolic conditions, and over three million mRNA measurements. The BXD transcriptome has been densely sampled across brain and peripheral tissue and is represented by more than 80 independent data sets using a wide variety of platforms—^{98,99}. Recent work by multiple investigators includes the generation of miRNA, proteomic, metabolomic, epigenomic, and metagenomic data for the BXDs ⁴. This assemblage of

quantitative data has been integrated into GeneNetwork and the Mouse Phenome database ^{100,101} and is freely accessible both as individual data sets or in its entirety.

The size and depth of the multiscalar phenome constructed for the BXD family makes it an excellent resource for systems genetic and genomics, as well as a foundation for experimental precision medicine. The genetic architecture of one or many traits can be dissected and relations between traits exposed. The ability to resample genotypes across a stable genetic reference population enables the expansion of the phenome in almost any direction and including cellular and molecular phenotypes at any stage. There are two main obstacles: The first is the development of structured and controlled vocabulary or ontologies for phenotypes that allows for cross-species translation and bioinformatic analyses. The second problem sounds trivial but is actually difficult—getting a large and diverse community of biomedical researchers engaged in using replicable genetic resources and then in providing their extremely valuable core phenotype data and metadata to curators and data integrators.

The BXD phenome encompasses multiple levels of data, from single molecules to complex behavioral repertoires, measured under standard or various environmental exposures, including alcohol and drugs of abuse ^{31,102–104}, infectious agents ^{92,105,106}, dietary modifications ^{81,82,107–110}, stress ^{111,112} and as a function of age. While this represents the largest phenome for any group of animals it is still an unbalanced phenome and has significant gaps that need to be filled, for example, in embryology, cellular and systems physiology, cardiovascular and urogenital systems. Major areas of research in

which the BXDs have experimental advantages over other systems are particularly in epigenetics and gene-environment interactions ⁴⁴.

Future Directions: Pleiotropy, epigenetics, gene by environment interactions and precision medicine in the extended BXD family

Most of the work carried out in the BXD family to date has had the simple goal of defining single causal gene variants and mechanisms that contribute to heritable differences in disease risk. But we need to tackle a complementary and far more challenging problem—the complex interplay among sets of variants, constellations of phenotypes (pleiotropy), and different treatments and environments ^{4,33,48,113}. Experimental cohorts such as the BXD family are ideal to achieve this goal, and are powerful experimental companions to human genetics and clinical research. These unique types of immortal murine families will make it possible to experimentally test the promise and limits of precision medicine.

Over the next decades large cohorts of humans and other species will be sequenced and analyzed using advanced molecular methods (e.g. ¹¹⁴). We will have access to sequence and electronic health records for millions of subjects (e.g. Million Veterans Projects ¹¹⁵ and UK Biobank; www.ukbiobank.ac.uk ^{116,117}), but will this be enough to address the main goals of precision health care—to accurately predict risk of disease before onset and to optimize prevention and therapeutics? Only when combined with advanced experimental systems such as the BXD panel or the Collaborative Cross will we be able to harness the full potential of conjoint multi-systems approaches ¹¹⁸.

Standard inbred strains of mice ^{119,120} and their RI progeny such as the BXDs and the Collaborative Cross ^{23,59} are a good resource with which to test the limits of precision medicine. They enable a community of researchers in disparate fields to gradually assemble coherent phenomes of great size for isogenic lines with nearly complete sequence data ¹²¹. The BXDs excel in this dimension. But BXDs and other murine populations should not be used to the exclusion of other resources. For example, BXDs and other isogenic lines of mice, including common inbred strains, the Collaborative Cross, and panels of congenic lines can all be used jointly. The statistical analysis of complex admixed cohorts is now computationally tractable ¹²² using the same algorithms used to handle admixed human GWAS cohorts. Williams and colleagues and Lusi and colleagues have been systematically using a "hodge-podge" of up to 100 isogenic strains (what is now called a hybrid mouse diversity panel) in joint systems genetic studies of many clinically relevant traits ^{75,123–127}. Indeed, combined mouse QTLs and human GWASs have identified novel candidates and pathways illustrating the translational value of experimental data from RI populations ^{2,77,131,78–82,128–130}.

The BXD family of 150 strains is now an appropriate number of genomes to evaluate predictive modeling of biological processes and disease risk, and for developing computational models of genome-to-phenome relations ^{3,90,132}. In a two-parent RI family such as the BXDs minor allele frequency is of course close to 0.5 for most variants. Furthermore, there are only four two-locus combinations (BB/BB; BB/DD DD/BB, and DD/DD). Thus with 100 strains each of these four combinations will typically (95% of the time) be represented by 16 or more strains. The BXDs are therefore large enough to

enable the analysis of epistatic interactions with good power. But the power to study epistasis can be greatly amplified by crossing BXD strains to generate a DX. With a subset of 100 BXD strains, it is possible to generate 9900 reciprocal pairs of DX F1 progeny. For example, crosses of female BXD99 to male BXD100 and vice versa give rise to 99X100 and 100X99 isogenic DX progeny. These reciprocal DX pairs generally do not differ for either mitochondrial or Chr Y since these are both fixed as *B* and *D* haplotypes, respectively, in the BXDs (but there are exceptions).

Reciprocal diallel crosses (reciprocal DXs) have been used to investigate parent-of-origin effects on ultrasonic vocalization ¹⁴. In F1 reciprocal crosses between most isogenic strains, females have identical nuclear genomes, differing only in their mitochondrial genome, whereas males will also differ in their sex chromosomes. This allows the investigation of parent-of-origin and sex chromosome effects ¹³³. This makes them almost uniquely suited for the investigation of parent-of-origin effects. As well as expanding the number of isogenic mice in the BXD family from 150 to over 22,000, BXD animals can also be crossed to other strains. Isogenic strains can be crossed to traditional mutant mouse models to investigate the effect of diverse genetic backgrounds on mutations linked to human diseases ^{134–136}. Neuner et al. crossed a subset of the BXD panel to the transgenic and humanized Alzheimer's Disease (AD) 5XFAD model ¹³⁷ to produce F1 hybrid transgenic AD-BXDs, and were able to demonstrate a profound effect of genetic background on both cognitive and physiological phenotypes ¹³⁴. This provides an entirely new avenue of investigation using resources such as the animals generated from the International Mouse Phenotyping Consortium (IMPC;

<http://www.mousephenotype.org/>)¹³⁸, Mutant Mouse Resource & Research Centers (MMRRC; <https://www.mmrrc.org/>) and Knockout Mouse project (KOMP; <https://www.komp.org>). By crossing humanized or interesting genetically engineered lines on a single genetic background to genetically defined individuals from a diverse population, variants which modify traits of interest can be mapped, thus elucidating epistatic interactions, and providing information on disease course, not just disease risk. Again, this provides a model that approximates a human population, with the exception that individual genomes can be resampled infinitely.

We now need to rethink the best uses of mouse models for complex trait analysis. The main reason is that the original challenge of achieving high mapping precision has been largely overcome in human genome-wide association studies (GWAS Catalog at www.ebi.ac.uk/gwas). Tens of thousands of variants have been mapped to small haplotype blocks—usually under 200 Kb—for a broad spectrum of human traits—from differences in mRNA expression to stature and schizophrenia^{139–141}. This is only the beginning. The precision and the power in human genetics will improve greatly over the next several decades as full genome sequences, better human disease phenotyping, and electronic health records are merged at the scale of millions of subjects and whole nations. Therefore, we need to revamp experimental genetic resources in an era flooded in GWAS hits. How are new and old mouse resources best repositioned to help deliver on the still unmet and much more integrative promises of predictive genetics and personalized precision health care?

The short answer is that we need large genetically complex resources with matched multiscalar and multisystems phenome data that can be used to test and predict effects of interventions, drugs, and other gene-by-environment interactions. We need resources that define and test progressively more sophisticated computational models as a function of genotype, case history and exposure. We need replicable mouse populations with the same level of genetic complexity as human cohorts but without the many disadvantages of clinical research—high cost, poor compliance and control, confidentiality constraints, and importantly, ethical limitations on experimental procedures. Mouse populations—including large families of recombinant inbred strains and their isogenic but non-inbred RI F1 diallele crosses (DX cohorts)—are ideally positioned to be the experimental test bed with which to define the power and limits of precision health care.

Conclusions

Systems genetics using mouse models has been revitalized over the last decade thanks to several new resources, including the BXD family of recombinant inbred strains²⁰, the Hybrid Mouse Diversity Panel (HMDP;^{121,126} and the Collaborative Cross (CC)^{142–145}. Mouse models stand as an excellent resource to test hypotheses and explore mechanisms in the new era of precision medicine, working in combination with new genomics tools available in human cohorts. The main limitation has been relatively modest mapping power and precision—a simple problem caused by small numbers of strains. With 150 strains now readily available, the BXD family has overcome this problem.

Methods and Materials

BXD strains

Between 2009 and 2010 we initiated 74 BXD strains (BXD104 to BXD186). We initiated another 34 strains in 2013 (BXD187 to BXD220). We used both conventional F2 intercrosses ($n = 88$) and AI progeny ($n = 20$) to make the 108 new lines. BXD160 through BXD186 were derived from unique matings of AI progeny gifted us by Dr. Abraham Palmer at G8 and G9 late in 2010 (Figure 1, Supplementary figure 1, Supplementary table 1).

In cases of low reproductive fitness, we often attempted to rescue lines by outcrossing young male BXDs to C57BL/6J females followed by three of more sequential backcrosses (N3) to the RI male to produce progeny enriched for the BXD genome. In more recent cases, pairs of at risk strains were crossed to produce RIX progeny^{23,50}, which were then inbred by sibling mating. BXD221 to BXD228 are RIX-derived strains of this type (Supplementary figure 1, Supplementary table 1).

Unless otherwise specified, all animals used in this study were raised in a closed-barrier pathogen-free vivarium at the University of Tennessee Health Science Center. All BXD strains are available under a standard material transfer agreement; the most important limitation being that they cannot be sold or distributed without approval of the Jackson Laboratory or UTHSC. Availability information on all BXD lines can be found in Supplemental Table 1.

Genetic map construction and genotype error correction

Individuals from each of the 198 BXD lines were genotyped in late 2011 and in late 2015 using the Neogen/GeneSeek MUGA or GigaMUGA arrays. These were combined with previous genotypes generated using Affymetrix and MUGA platforms. Unknown genotypes were imputed as B (C57BL/6J-like) or D (DBA/2J-like), or were called as H (heterozygous) if the genotype was uncertain.

The full dataset contains 37,000 markers and was optimized for mapping efficiency by excluding markers showing identical strain distribution patterns. Markers that flank sites of recombination were retained. As a result, strain distribution patterns are often defined by proximal-distal marker pairs. Whenever possible, we verified and updated genotypes of the original BXD strains (BXD1 - BXD102) to reflect those of stock available from the Jackson Laboratory (⁸³ and from Petr Simecek and Gary Churchill; <http://cgd.jax.org/datasets/diversityarray.shtml>).

Genotypes for all strains were smoothed and curated to remove highly implausible (double) recombination events, e.g. unsupported genotypes (singletons) that introduced two recombination events over less than 100 kb ²³. In general, we imputed unknown or heterozygous genotypes on the basis of flanking markers. Undefined genotypes between recombinations were coded as heterozygous, and telomere genotypes were imputed using the closest flanking marker.

In the newer BXD strains there are many regions that are still heterozygous. Generated genotypes using standard platforms still show regions of low marker density and a high frequency of recombinations. These regions of low marker density were filled

with imputed genotypes using *cis*-eQTLs of genes in the problematic intervals.

Microsatellites and *cis*-eQTL genotypes were generated by the Williams/Lu laboratory.

The assembled and error checked genotype file includes 7,324 markers for 191 independent strains, and 7 substrains, has been available since January 2017 at <http://www.genenetwork.org/genotypes/BXD.geno> and is the default genetic map used when QTL mapping on GeneNetwork (<http://www.genenetwork.org>).

Computing centi-Morgan positions

For each chromosome we compute the number of observed recombinations from one position to the next, ignoring the heterozygous and unknown genotypes (nRecP). We then compute the recombination fraction (R) by dividing the number of recombinations observed (nRecP) by the population size used to generate the genetic map. The recombination fractions (R) are then deflated using the formula:

$$r = R / (4 - 6R)$$

, which is the inverse of the formula $R = 4r / (1 + 6r)$ for a recombinant inbred line by sibling mating. We then use the function `imf.cf` available in the R package `R/qtl`^{64,146} to convert from centiMorgan using the Carter-Falconer map function¹⁴⁷. Positions obtained start at 0 on each chromosome, requiring all positions to be shifted so that the first marker on the map matches the known centiMorgan position of the first marker on the genetic map. The old genetic map and the `mousemapconverter` (<http://cgd.iax.org/mousemapconverter/>) were used to obtain centiMorgan positions for the first marker on a chromosome, all position on a chromosome are shifted to align the genetic map to the known starting positions of the markers. Code for computing marker

positions is available in the BXDtools package (<https://github.com/DannyArends/BXDtools>), and positions can be recomputed using different map functions when required (e.g. Haldane ¹⁴⁸, Kosambi ¹⁴⁹, Morgan ¹⁵⁰).

Genome wide visualization of recombinations

For each chromosome we compute the number of observed recombinations per strain from the start of the chromosome (nRecS), ignoring the heterozygous and unknown genotypes. We then visualize this by plotting the number of recombinations for each BXD strain per chromosome using a color gradient. Strain numbers are used for the ordering on the X-axis, and horizontal lines are added to visually separate the different epochs and annotate the epochs on the X-axis.

Comparing genotype files

During the BXD's 40+ years of existence, several genotype files have been used for QTL mapping. The first, genome-wide map (which we call the 'original') was used pre-2001, and contained 1578 microsatellites ²³. The second 'classic' map was used between 2001-2016 and contained 3811 SNPs from various microarrays ¹⁵¹. The third, 'current' post-2017, used 7321 SNPs and is described above.

For the pre-2001 microsatellites, Mouse Genome Informatics was used to determine updated (mm10) positions for 1419 of the probes, but this left 159 without mm10 positions. We used NCBI Probe database (<https://www.ncbi.nlm.nih.gov/probe/>) to search for these 159 probes, and for 107 we were able to get primer sequences. For these sequences, we then ran Primer-BLAST

(<https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi>) to determine where in the mm10 genome they would amplify. For the remaining 52 markers, we used BLAST to align the target sequence to mm10 to identify the mm10 position. This left 11 markers which Primer-BLAST either predicted a different chromosome would be amplified, or which did not have any mm10 genomic targets.

These ‘original’ genotypes only exist for the first 36 BXD strains (BXD1-42), and so the remaining strains were imputed (BXD24a and BXD 43+), using the genotype at the microsatellite’s position in the ‘current’ post-2017 genotyping file. To determine our power to detect QTLs, we ran mapping using QTLreaper for the 7562 phenotypes collected for the BXD, and the number of phenotypes which had an LRS greater than three threshold values: 15, 20 and 25. These correspond to suggestive, significant and highly significant LRS values. The larger the number of phenotypes above these thresholds, the greater our power to detect QTLs.

Precision and Resolution

To estimate empirical precision of mapping across the genome we have extracted data from 40 large-scale genetic studies of gene expression of the BXD family. These studies used between 21 and 79 strains with variable numbers of within-strain replicates, over 27 tissues. We defined eQTLs that map within ± 20 Mb of the gene associated with the transcript's measurement as a *cis*-acting expression QTLs (*cis*-eQTLs). Unlike a standard F2 intercross, this ± 20 Mb window is roughly equivalent to a recombination distance of ± 40 cM in the highly recombinant BXD family, and the statistical association between markers this far apart is generally quite low (r^2 less than 0.3).

Precision was estimated using the offset between the location of the gene (using the 5' end of the probe or probe set as a reference point), and the location of the SNP with the highest LOD score. Again, this is conservative, as the causal variant is unlikely to be exactly at the 5' end of the gene. There are often two or more neighboring SNPs with equally high LOD scores and we simply take the most proximal marker to compute offset. The light blue local regression (LOESS) smoother curve¹⁵² was computed using a window with a size of 0.333% of the genome. Smoothing was carried out and data was plotted using the *ggplot2* R package.

QTL mapping

QTL mapping using GeneNetwork has been described in detail elsewhere⁸⁷. However, in brief, quantitative trait loci (QTLs) are segments of the genome affecting a particular phenotype¹⁵³. QTL mapping, identifying QTLs to explain the genetic basis of complex traits, relies on being able to make correlations between genetic markers and phenotypic traits in a population. Individuals are scored for their phenotype for a particular trait, and their genotype at a marker. If there is a difference in mean phenotype between those individuals with one genotype compared with the other than we can infer that there is a QTL linked to that marker. If there is no difference between the means we can conclude that the loci does not influence the phenotype in that population^{153,154}.

Due to the very high density of markers, the mapping algorithm used to map BXD data sets has been modified and is a mixture of simple marker regression, linear interpolation, and standard Haley-Knott interval mapping¹⁵⁵. When two adjacent

markers have identical strain distribution patterns, they will have identical linkage statistics, as will the entire interval between these two markers (assuming complete and error-free haplotype data for all strains). On a physical map the LRS and the additive effect values will therefore be constant over this physical interval. Between neighboring markers that have different strain distribution patterns and that are separated by 1 cM or more, we use a conventional interval mapping method (Haley-Knott) combined with a Haldane estimate of genetic distance. When the interval is less than 1 cM, we simply interpolate linearly between markers based on a physical scale between those markers. The result of this mixture mapping algorithm is a linkage map of a trait that has an unusual profile that is particular striking on a physical (Mb) scale, with many plateaus, abrupt linear transitions between plateaus, and a few regions with the standard graceful curves typical of interval maps.

Prior to the 2017 release of the genotypes described in this manuscript interval mapping in GeneNetwork relied on 3,795 informative SNP markers across all autosomes and the X chromosome ¹⁵¹. These markers were generated using the MUGA array in 2011, along with earlier generated genotypes on the Affymetrix and Illumina platforms ⁶⁷. As described above, loci are identified in GeneNetwork by the computation of a likelihood ratio statistic score and significance was determined using at least 5,000 permutations of the phenotype data.

Updated QTL mapping methods, such as R/qtl2 ^{66,146}, Multiple QTL mapping ⁶⁴, GEMMA ¹⁵⁶ and pyLMM ⁶³, have been implemented on the GeneNetwork2 site ⁴⁶. GEMMA, and pyLMM allow to account for kinship between BXD strains by computing a

genetic kinship matrix given specific strains used in an analysis, allowing for precise kinship correction and improved QTL mapping performance when mapping any of the BXD phenotypes in the GeneNetwork database.

Phenome wide association (PheWAS)

Phenome-wide association studies (PheWAS) associates a single genetic marker with a rich set of phenotype data, to investigate a phenotypic and pleiotropic effects of a genetic marker. PheWAS is related to GWAS, and PheWAS can be characterized a GWAS on its side, investigating if the genetic variants linked to this marker influence multiple phenome categories. Phenotype data is first grouped in so called phenomes, groups of phenotypes which are functionally, physiologically or genetically related to each other. To visualize the PheWAS scan, phenotypes are put on the X-axis, and strength of association (either in LOD or LRS) is put on the Y-axis. Significance thresholds were computed and adjusted based on Benjamini-Hochberg correction ¹⁵⁷, where the number of tests is equal to the number of phenotypes in the PheWAS scan. The term PheWAS was first coined by Arends et al. while investigating longitudinal electronic medical records (EMRs) coupled to genetic data ¹⁵⁸. The (extended) BXD population is the most densely phenotyped and manually annotated inbred mouse population, and the extended BXD population allows for PheWAS with unprecedented precision. PheWAS is not yet integrated in the original GeneNetwork, but is available in the BXDtools package (<https://github.com/DannyArends/BXDtools>) and on the Systems-Genetics.org website (<https://www.systems-genetics.org/>) which will be integrated into GeneNetwork2 allowing for point and click PheWAS scans of the BXD phenome containing ~ 7000 classical

phenotypes. Systems-Genetics.org also contain the tools for Mediation, reverse mediation and gene expression PheWAS (ePheWAS).

Power calculation

Power calculations were carried out based on the method of Sen and colleagues⁵⁷ and implemented in the R program *qtlDesign* based on the H^2_{RIX} defined by Belknap⁴⁷, which we renamed H^2_{IX} as it is applicable to any isogenic strain, not just recombinant inbreds. The *Detectable* function was used, to determine the power available with an RI design to detect a locus of a given effect size.

For calculation of the H^2_{IX} four variables need to be known: the broad sense heritability (H^2), the number of within-strain replicates (biological replicates), the number of strains used and the locus effect size (the proportion of total genetic variance explained by the locus). To calculate H^2 , the genomic variance (gen.var) was kept constant at 1, and the environmental variance (env.var) was varied to produce H^2 values ranging between 0 and 1. The number of biological replicates and number of strains are self-explanatory, and were capped at 10 and 150 respectively, since >10 replicates produced a marginal increase in power, and because there are 150 BXD lines currently available.

The locus effect size is the amount of the variance which is due to genetics (gen.var) explained by a single QTL. That is, a value of 0.2 would mean that a QTL explains 20% of the genetic variance, and a value of 1.0 indicates a Mendelian locus (one QTL which explains all of the genetic variance).

The power given is the ability of the experiment to correctly detect a true positive QTL, given the other values above. The BXD power app can be found at

https://dashbrook1.shinyapps.io/bxd_power_calculator_app/ and uses the *Shiny* R package (<https://CRAN.R-project.org/package=shiny>)

List of abbreviations

AD – Alzheimer’s Disease

AI – advanced intercross

B6 – C57BL/6J mouse strain

BLAST – Basic Local Alignment Search Tool

BXD – BXD family of recombinant inbred strains of mice, produced by crossing the

B6 and D2 parental strains

CC – Collaborative Cross

Chr – Chromosome

cM – centimorgan

D2 – DBA/2J mouse strain

DO – Diversity Outbred

DX – diallel cross

EMRs – electronic medical records

eQTL – Expression quantitative trait locus

F2 – Filial generation 2

GEMMA – Genome-wide Efficient Mixed Model Association

GigaMUGA – Giga Mouse Universal Genotyping Array

GN – GeneNetwork (<http://genenetwork.org>)

GN2 – GeneNetwork2 (<http://gn2.genenetwork.org>)

GWAS – genome-wide association study

$H^2_{i\bar{x}}$ – heritability of isogenic strain means

$H^2_{RI\bar{x}}$ – heritability of recombinant inbred strain means

HMDP – Hybrid Mouse Diversity Panel

IMPC – International Mouse Phenotyping Consortium

JAX – The Jackson Laboratory

Kb – kilobase

KOMP – Knockout Mouse project

LOD – logarithm of odds

LRS – likelihood ratio statistic

Mb – Megabase

MMRRC – Mutant Mouse Resource & Research Centers

MUGA – Mouse Universal Genotyping Array

nRecP – number of observed recombinations from one position to the next

nRecS – number of observed recombinations per strain

PheWAS – phenome-wide association studies

QT – quantitative trait

QTL – quantitative trait locus

r^2 – Coefficient of determination

RI – Recombinant inbred

RIXs – Recombinant inbred intercrosses

SE – Standard error of the mean

SNP – single nucleotide polymorphism

UTHSC – University of Tennessee Health Science Center

Declarations

Availability of data and material

The datasets generated and/or analyzed during the current study are available in the GeneNetwork repository, <https://www.genenetwork.org/>

Competing interests

The authors declare that they have no competing interests

Funding

We thank the support of the UT Center for Integrative and Translational Genomics, and funds from the UT-ORNL Governor's Chair, NIDA grant P30DA044223, NIAAA U01 AA013499 and U01 AA016662 for the work at UTHSC. The work in the Auwerx lab on the BXDs is supported by the Ecole Polytechnique Fédérale de Lausanne, the ERC (AdG-787702), the SNSF (310030B-160318), the AgingX program of the Swiss Initiative for Systems Biology (RTD 2013/153), and the NIH (R01AG043930). The BXD Resource at the Jackson Laboratory is supported by NIH P40 OD011102 awarded to Dr. Cathleen M. Lutz.

Acknowledgements

Our thanks to Dr. Abraham Palmer for providing us with valuable B6D2 advanced intercross progeny (G8 and G9) in 2011 that we used to make BXD160 through BXD186. We thank Dr. Benjamin A. Taylor for initiating the BXD family and for his continued support and encouragement. We thank members of the EPFL Center for Phenogenomics

in particular Drs. Xavier Warot and Emilie Gesina for sharing data from their BXD colony, and Erik Soehnel from Scionics for his assistance in obtaining the full breeding statistics. The UTHSC Center for Integrative and Translational Genomics (CITG) has supported the production of the BXD colony at UTHSC and will continue to support this colony for the duration of the grant. The CITG also provides generous support for computer hardware and programming associated with GeneNetwork, and our Galaxy and UCSC Genome Browser instances. Finally, the CITG as well as the UT-ORNL Governor's Chair endowment to RWW will help support the sequence analysis of the BXDs. This work is required to extract the interesting but small subset of rare private alleles that each strain accumulates during inbreeding.

References

1. Taylor, B. A., Heiniger, H. J. & Meier, H. Genetic analysis of resistance to cadmium-induced testicular damage in mice. *Proc. Soc. Exp. Biol. Med.* **143**, 629–633 (1973).
2. Andreux, P. A. *et al.* Systems genetics of metabolism: the use of the BXD murine reference panel for multiscalar integration of traits. *Cell* **150**, 1287–1299 (2012).
3. Wang, X. *et al.* Joint mouse-human phenome-wide association to test gene function and disease risk. *Nat. Commun.* **7**, 10464 (2016).
4. Williams, E. G. *et al.* Systems proteomics of liver mitochondria function. *Science* **352**, aad0189 (2016).
5. Williams, R. W. & Williams, E. G. Resources for Systems Genetics. in *System Genetics: Methods and Protocols* (eds. Schughart, K. & Williams, R. W.) **1488**, 3–

29 (Springer New York, 2017).

6. Taylor, B. A. *et al.* Genotyping new BXD recombinant inbred mouse strains and comparison of BXD and consensus maps. *Mamm. Genome* **10**, 335–348 (1999).
7. Grizzle, W. E. *et al.* BXD recombinant inbred mice represent a novel T cell-mediated immune response tumor model. *Int. J. cancer* **101**, 270–279 (2002).
8. Lee, G. H., Bennett, L. M., Carabeo, R. A. & Drinkwater, N. R. Identification of hepatocarcinogen-resistance genes in DBA/2 mice. *Genetics* **139**, 387–395 (1995).
9. McGinnis, J. F., Lerious, V., Pazik, J. & Elliott, R. W. Chromosomal assignment of the recoverin gene and cancer-associated retinopathy. *Mamm. Genome* **4**, 43–45 (1993).
10. Seecharan, D. J., Kulkarni, A. L., Lu, L., Rosen, G. D. & Williams, R. W. Genetic control of interconnected neuronal populations in the mouse primary visual system. *J. Neurosci.* **23**, 11178–11188 (2003).
11. Rosen, G. D. *et al.* Genetic modulation of striatal volume by loci on Chrs 6 and 17 in BXD recombinant inbred mice. *Genes. Brain. Behav.* **8**, 296–308 (2009).
12. Belknap, J. K., Phillips, T. J. & O'Toole, L. A. Quantitative trait loci associated with brain weight in the BXD/Ty recombinant inbred mouse strains. *Brain Res. Bull.* **29**, 337–344 (1992).
13. Zhou, G. & Williams, R. W. Eye1 and Eye2: gene loci that modulate eye size, lens weight, and retinal area in the mouse. *Invest. Ophthalmol. Vis. Sci.* **40**, 817–825 (1999).
14. Ashbrook, D. G. *et al.* Born to Cry: A Genetic Dissection of Infant Vocalization.

- Front. Behav. Neurosci.* **12**, 250 (2018).
15. Knoll, A. T., Jiang, K. & Levitt, P. Quantitative trait locus mapping and analysis of heritable variation in affiliative social behavior and co-occurring traits. *Genes. Brain. Behav.* **17**, e12431 (2018).
 16. Belknap, J. K. *et al.* Single-locus control of saccharin intake in BXD/Ty recombinant inbred (RI) mice: Some methodological implications for RI strain analysis. *Behav. Genet.* **22**, 81–100 (1992).
 17. Weimar, W. R., Lane, P. W. & Sidman, R. L. Vibrator (vb): a spinocerebellar system degeneration with autosomal recessive inheritance in mice. *Brain Res.* **251**, 357–364 (1982).
 18. Grisel, J. E. *et al.* Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains. *J. Neurosci.* **17**, 745–754 (1997).
 19. Belknap, J. K. *et al.* Quantitative trait loci (QTL) applications to substances of abuse: physical dependence studies with nitrous oxide and ethanol in BXD mice. *Behav. Genet.* **23**, 213–222 (1993).
 20. Peirce, J. L., Lu, L., Gu, J., Silver, L. M. & Williams, R. W. A new set of BXD recombinant inbred lines from advanced intercross populations in mice. *BMC Genet.* **5**, 7 (2004).
 21. Chesler, E. J. *et al.* Genetic correlates of gene expression in recombinant inbred strains: a relational model system to explore neurobehavioral phenotypes. *Neuroinformatics* **1**, 343–357 (2003).
 22. Darvasi, A. Experimental strategies for the genetic dissection of complex traits in

- animal models. *Nat. Genet.* **18**, 19–24 (1998).
23. Williams, R. W., Gu, J., Qi, S. & Lu, L. The genetic structure of recombinant inbred mice: high-resolution consensus maps for complex trait analysis. *Genome Biol.* **2**, RESEARCH0046 (2001).
 24. Parker, C. C., Sokoloff, G., Cheng, R. & Palmer, A. A. Genome-wide association for fear conditioning in an advanced intercross mouse line. *Behav. Genet.* **42**, 437–448 (2012).
 25. Parker, C. C., Cheng, R., Sokoloff, G. & Palmer, A. A. Genome-wide association for methamphetamine sensitivity in an advanced intercross mouse line. *Genes. Brain. Behav.* **11**, 52–61 (2012).
 26. Pandey, A. K. & Williams, R. W. Genetics of gene expression in CNS. *Int. Rev. Neurobiol.* **116**, 195–231 (2014).
 27. Wu, Y. *et al.* Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. *Cell* **158**, 1415–1430 (2014).
 28. Wang, L. S. *et al.* Critical evaluation of transcription factor Atf2 as a candidate modulator of alcohol preference in mouse and human populations. *Genet. Mol. Res.* **12**, 5992–6005 (2013).
 29. Mulligan, M. K. *et al.* Expression, covariation, and genetic regulation of miRNA Biogenesis genes in brain supports their role in addiction, psychiatric disorders, and disease. *Front. Genet.* **4**, 126 (2013).
 30. Dickson, P. E. *et al.* Systems genetics of intravenous cocaine self-administration in the BXD recombinant inbred mouse panel. *Psychopharmacology (Berl)*. **233**, 701–

714 (2016).

31. Dickson, P. E. *et al.* Systems genetics of sensation seeking. *Genes. Brain. Behav.* **18**, e12519 (2019).
32. Graybeal, C. *et al.* Strains and stressors: an analysis of touchscreen learning in genetically diverse mouse strains. *PLoS One* **9**, e87745 (2014).
33. Mulligan, M. K. & Williams, R. W. Systems genetics of behavior: a prelude. *Curr. Opin. Behav. Sci.* **2**, 108–115 (2015).
34. Carhuatanta, K. A. K., Shea, C. J. A., Herman, J. P. & Jankord, R. Unique genetic loci identified for emotional behavior in control and chronic stress conditions. *Front. Behav. Neurosci.* **8**, 341 (2014).
35. Philip, V. M. *et al.* High-throughput behavioral phenotyping in the expanded panel of BXD recombinant inbred strains. *Genes. Brain. Behav.* **9**, 129–159 (2010).
36. Hayes, K. S., Hager, R. & Grencis, R. K. Sex-dependent genetic effects on immune responses to a parasitic nematode. *BMC Genomics* **15**, 193 (2014).
37. McKnite, A. M. *et al.* Murine gut microbiota is defined by host genetics and modulates variation of metabolic traits. *PLoS One* **7**, e39191 (2012).
38. Ashbrook, D. G., Sharmin, N. & Hager, R. Offspring genes indirectly influence sibling and maternal behavioural strategies over resource share. *Proceedings. Biol. Sci.* **284**, 20171059 (2017).
39. Ashbrook, D. G., Gini, B. & Hager, R. Genetic variation in offspring indirectly influences the quality of maternal behaviour in mice. *Elife* **4**, e11814 (2015).
40. Baud, A. *et al.* Genetic variation in the social environment contributes to health

- and disease. *PLoS Genet.* **13**, e1006498 (2017).
41. Hager, R., Lu, L., Rosen, G. D. & Williams, R. W. Genetic architecture supports mosaic brain evolution and independent brain-body size regulation. *Nat. Commun.* **3**, 1079 (2012).
 42. Oren, Y., Nachshon, A., Frishberg, A., Wilentzik, R. & Gat-Viks, I. Linking traits based on their shared molecular mechanisms. *Elife* **4**, (2015).
 43. Keane, T. M. *et al.* Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature* **477**, 289–294 (2011).
 44. Baker, C. L. *et al.* Tissue-specific trans regulation of the mouse epigenome. *Genetics* genetics.301697.2018 (2018). doi:10.1534/genetics.118.301697
 45. Li, H. *et al.* An Integrated Systems Genetics and Omics Toolkit to Probe Gene Function. *Cell Syst.* **6**, 90-102.e4 (2018).
 46. Sloan, Z. *et al.* GeneNetwork: framework for web-based genetics. *J. Open Source Softw.* **1**, 25 (2016).
 47. Belknap, J. K. Effect of within-strain sample size on QTL detection and mapping using recombinant inbred mouse strains. *Behav. Genet.* **28**, 29–38 (1998).
 48. Williams, E. G. & Auwerx, J. The convergence of systems and reductionist approaches in complex trait analysis. *Cell* **162**, 23–32 (2015).
 49. Hood, L. & Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. *N. Biotechnol.* **29**, 613–624 (2012).
 50. Tsaih, S.-W., Lu, L., Airey, D. C., Williams, R. W. & Churchill, G. A. Quantitative trait

- mapping in a diallel cross of recombinant inbred lines. *Mamm. Genome* **16**, 344–355 (2005).
51. Airey, D. C., Lu, L., Shou, S. & Williams, R. W. Genetic sources of individual differences in the cerebellum. *Cerebellum* **1**, 233–240 (2002).
 52. Morgan, A. P. *et al.* The mouse universal genotyping array: From substrains to subspecies. *G3 (Bethesda)*. **6**, 263–279 (2015).
 53. Zhang, W. *et al.* Genome-wide association mapping of quantitative traits in outbred mice. *G3 (Bethesda)*. **2**, 167–174 (2012).
 54. Brownstein, D. G., Bhatt, P. N., Gras, L. & Jacoby, R. O. Chromosomal locations and gonadal dependence of genes that mediate resistance to ectromelia (mousepox) virus-induced mortality. *J. Virol.* **65**, 1946–1951 (1991).
 55. Ashbrook, D. G. *et al.* Sequencing the BXD family, a cohort for experimental systems genetics and precision medicine. in *2018 IBANGS MEETING: THE 20TH ANNUAL GENES, BRAIN & BEHAVIOR MEETING* 4–5 (International Behavioral and Neural Genetics Society, 2018).
 56. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* **507**, 371–375 (2014).
 57. Sen, Ś., Satagopan, J. M., Broman, K. W. & Churchill, G. A. R/qtldesign: Inbred line cross experimental design. *Mamm. Genome* **18**, 87–93 (2007).
 58. Williams, R. W. *et al.* Integrated complex trait analysis of brain and behavior in mouse: near-term prospects for high-resolution QTL mapping using large RI and RIX sets. in *The 4th Annual Meeting of the International Behavioural and Neural*

Genetics Society (2001).

59. Threadgill, D. W., Hunter, K. W. & Williams, R. W. Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort. *Mamm. Genome* **13**, 175–178 (2002).
60. Beavis, W. D. QTL analyses: power, precision, and accuracy. in *Molecular dissection of complex traits* (ed. Paterson, A. H.) 145–162 (CRC Press, 1998).
61. Allison, D. B. *et al.* Bias in estimates of quantitative-trait-locus effect in genome scans: demonstration of the phenomenon and a method-of-moments procedure for reducing bias. *Am. J. Hum. Genet.* **70**, 575–585 (2002).
62. Zhou, X. & Stephens, M. Efficient multivariate linear mixed model algorithms for genome-wide association studies. *Nat. Methods* **11**, 407–409 (2014).
63. Sul, J. H. *et al.* Accounting for Population Structure in Gene-by-Environment Interactions in Genome-Wide Association Studies Using Mixed Model. *PLoS Genet.* **12**, e1005849 (2016).
64. Arends, D., Prins, P., Jansen, R. C. & Broman, K. W. R/qtl: high-throughput multiple QTL mapping. *Bioinformatics* **26**, 2990–2992 (2010).
65. Stephan, J., Stegle, O. & Beyer, A. A random forest approach to capture genetic effects in the presence of population structure. *Nat. Commun.* **6**, 7432 (2015).
66. Broman, K. W. *et al.* R/qtl2: Software for mapping quantitative trait loci with high-dimensional data and multiparent populations. *Genetics* **211**, 495–502 (2019).
67. Shifman, S. *et al.* A high-resolution single nucleotide polymorphism genetic map of the mouse genome. *PLoS Biol.* **4**, 2227–2237 (2006).

68. Mulligan, M. K. *et al.* Identification of a functional non-coding variant in the GABAA Receptor $\alpha 2$ subunit of the C57BL/6J mouse reference genome: Major implications for neuroscience research. *Front. Genet.* **10**, 188 (2019).
69. Reed, C. *et al.* A spontaneous mutation in Taar1 impacts methamphetamine-related traits exclusively in DBA/2 mice from a single vendor. *Front. Pharmacol.* **8**, 993 (2017).
70. Anderson, M. G. *et al.* Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. *Nat. Genet.* **30**, 81–85 (2002).
71. Shin, D.-L. *et al.* Segregation of a spontaneous Klrd1 (CD94) mutation in DBA/2 mouse substrains. *G3 (Bethesda)*. **5**, 235–239 (2014).
72. Huang, T.-T. *et al.* Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. *Hum. Mol. Genet.* **15**, 1187–1194 (2006).
73. Mulligan, M. K. *et al.* Complex control of GABA(A) receptor subunit mRNA expression: variation, covariation, and genetic regulation. *PLoS One* **7**, e34586 (2012).
74. Dalton, T. P. *et al.* Identification of mouse SLC39A8 as the transporter responsible for cadmium-induced toxicity in the testis. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 3401–3406 (2005).
75. Williams, R. W., Strom, R. C. & Goldowitz, D. Natural variation in neuron number in mice is linked to a major quantitative trait locus on Chr 11. *J. Neurosci.* **18**, 138–146 (1998).
76. Houtkooper, R. H. *et al.* Mitonuclear protein imbalance as a conserved longevity

- mechanism. *Nature* **497**, 451–457 (2013).
77. Chintalapudi, S. R. *et al.* Systems genetics identifies a role for *Cacna2d1* regulation in elevated intraocular pressure and glaucoma susceptibility. *Nat. Commun.* **8**, 1755 (2017).
 78. Koutnikova, H. *et al.* Identification of the *UBP1* locus as a critical blood pressure determinant using a combination of mouse and human genetics. *PLoS Genet.* **5**, e1000591 (2009).
 79. Ashbrook, D. G. *et al.* Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease. *BMC Genomics* **15**, 850 (2014).
 80. Ashbrook, D. G., Williams, R. W., Lu, L. & Hager, R. A cross-species genetic analysis identifies candidate genes for mouse anxiety and human bipolar disorder. *Front. Behav. Neurosci.* **9**, 171 (2015).
 81. Jha, P. *et al.* Systems analyses reveal physiological roles and genetic regulators of liver lipid species. *Cell Syst.* **6**, 722–733.e6 (2018).
 82. Jha, P. *et al.* Genetic regulation of plasma lipid species and their association with metabolic phenotypes. *Cell Syst.* **6**, 709–721.e6 (2018).
 83. Rau, C. D. *et al.* High-density genotypes of inbred mouse strains: Improved power and precision of association mapping. *G3 (Bethesda)*. **5**, 2021–2026 (2015).
 84. Simecek, P. *et al.* High-Resolution Maps of Mouse Reference Populations. *G3 (Bethesda)*. **7**, 3427–3434 (2017).
 85. Williams, E. G. *et al.* Quantifying and localizing the mitochondrial proteome

across five tissues in a mouse population. *Mol. Cell. Proteomics* **17**, 1766–1777 (2018).

86. King, R., Lu, L., Williams, R. W. & Geisert, E. E. Transcriptome networks in the mouse retina: An exon level BXD RI database. *Mol. Vis.* **21**, 1235–1251 (2015).
87. Mulligan, M. K., Mozhui, K., Prins, P. & Williams, R. W. GeneNetwork: A Toolbox for Systems Genetics. *Methods Mol. Biol.* **1488**, 75–120 (2017).
88. Gonzales, N. M. & Palmer, A. A. Fine-mapping QTLs in advanced intercross lines and other outbred populations. *Mamm. Genome* **25**, 271–292 (2014).
89. Miyairi, I. *et al.* The p47 GTPases *ligp2* and *Irgb10* regulate innate immunity and inflammation to murine *Chlamydia psittaci* infection. *J. Immunol.* **179**, 1814–1824 (2007).
90. Miyairi, I. *et al.* Host genetics and Chlamydia disease: prediction and validation of disease severity mechanisms. *PLoS One* **7**, e33781 (2012).
91. Mozhui, K. *et al.* Dissection of a QTL hotspot on mouse distal chromosome 1 that modulates neurobehavioral phenotypes and gene expression. *PLoS Genet.* **4**, e1000260 (2008).
92. Boon, A. C. M., Williams, R. W., Sinasac, D. S. & Webby, R. J. A novel genetic locus linked to pro-inflammatory cytokines after virulent H5N1 virus infection in mice. *BMC Genomics* **15**, 1017 (2014).
93. Li, Z. *et al.* A transposon in *Comt* generates mRNA variants and causes widespread expression and behavioral differences among mice. *PLoS One* **5**, e12181 (2010).
94. Neuner, S. M. *et al.* Systems genetics identifies *Hp1bp3* as a novel modulator of

- cognitive aging. *Neurobiol. Aging* **46**, 58–67 (2016).
95. Williams, E. G. *et al.* An evolutionarily conserved role for the aryl hydrocarbon receptor in the regulation of movement. *PLoS Genet.* **10**, e1004673 (2014).
 96. Parker, C. C., Dickson, P. E., Philip, V. M., Thomas, M. & Chesler, E. J. Systems Genetic Analysis in GeneNetwork.org. *Curr. Protoc. Neurosci.* **79**, 8.39.1-8.39.20 (2017).
 97. Chesler, E. J., Lu, L., Wang, J., Williams, R. W. & Manly, K. F. WebQTL: rapid exploratory analysis of gene expression and genetic networks for brain and behavior. *Nat. Neurosci.* **7**, 485–6 (2004).
 98. Chesler, E. J. *et al.* Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. *Nat. Genet.* **37**, 233–242 (2005).
 99. Williams, R. W. & Mulligan, M. K. Genetic and molecular network analysis of behavior. *Int. Rev. Neurobiol.* **104**, 135–157 (2012).
 100. Bogue, M. A. *et al.* Mouse Phenome Database: an integrative database and analysis suite for curated empirical phenotype data from laboratory mice. *Nucleic Acids Res.* (2017). doi:10.1093/nar/gkx1082
 101. Bult, C. J. Chapter Four - Bioinformatics Resources for Behavior Studies in the Laboratory Mouse. in *Bioinformatics of Behavior: Part 2* (ed. Neurobiology, E. J. C. and M. A. H. B. T.-I. R. of) **Volume 104**, 71–90 (Academic Press, 2012).
 102. Théberge, E. T. *et al.* Genetic influences on the amount of cell death in the neural tube of BXD mice exposed to acute ethanol at mid-gestation. *Alcohol. Clin. Exp.*

- Res.* (2018). doi:10.1111/acer.13947
103. Zhou, D. *et al.* Ethanol's effect on Coq7 expression in the hippocampus of mice. *Front. Genet.* **9**, 602 (2018).
 104. Mulligan, M. K. *et al.* Genetic contribution to initial and progressive alcohol intake among recombinant inbred strains of mice. *Front. Genet.* **9**, 370 (2018).
 105. Chella Krishnan, K. *et al.* Genetic architecture of group a streptococcal necrotizing soft tissue infections in the mouse. *PLoS Pathog.* **12**, e1005732 (2016).
 106. Russo, L. M., Abdeltawab, N. F., O'Brien, A. D., Kotb, M. & Melton-Celsa, A. R. Mapping of genetic loci that modulate differential colonization by *Escherichia coli* O157:H7 TUV86-2 in advanced recombinant inbred BXD mice. *BMC Genomics* **16**, 947 (2015).
 107. Rodrigues, B. de A. *et al.* Obesity increases mitogen-activated protein kinase phosphatase-3 levels in the hypothalamus of mice. *Front. Cell. Neurosci.* **11**, 313 (2017).
 108. Jones, B. C. & Jellen, L. C. Systems genetics analysis of iron and its regulation in brain and periphery. *Methods Mol. Biol.* **1488**, 467–480 (2017).
 109. Reyes Fernandez, P. C., Replogle, R. A., Wang, L., Zhang, M. & Fleet, J. C. Novel genetic loci control calcium absorption and femur bone mass as well as their response to low calcium intake in male BXD recombinant inbred mice. *J. Bone Miner. Res.* **31**, 994–1002 (2016).
 110. Fleet, J. C. *et al.* Gene-by-Diet interactions affect serum 1,25-Dihydroxyvitamin D levels in male BXD recombinant inbred mice. *Endocrinology* **157**, 470–81 (2016).

111. Diessler, S. *et al.* A systems genetics resource and analysis of sleep regulation in the mouse. *PLoS Biol.* **16**, e2005750 (2018).
112. Jung, S. H., Brownlow, M. L., Pellegrini, M. & Jankord, R. Divergence in Morris Water Maze-based cognitive performance under chronic stress is associated with the hippocampal whole transcriptomic modification in mice. *Front. Mol. Neurosci.* **10**, 275 (2017).
113. Ashbrook, D. G. *et al.* Transcript co-variance with Nestin in two mouse genetic reference populations identifies Lef1 as a novel candidate regulator of neural precursor cell proliferation in the adult hippocampus. *Front. Neurosci.* **8**, 418 (2014).
114. Chen, R. *et al.* Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell* **148**, 1293–1307 (2012).
115. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J. Clin. Epidemiol.* **70**, 214–223 (2016).
116. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
117. Collins, R. What makes UK Biobank special? *Lancet (London, England)* **379**, 1173–1174 (2012).
118. Nadeau, J. H. & Auwerx, J. The virtuous cycle of human genetics and mouse models in drug discovery. *Nat. Rev. Drug Discov.* (2019). doi:10.1038/s41573-018-0009-9

119. Wade, C. M. *et al.* The mosaic structure of variation in the laboratory mouse genome. *Nature* **420**, 574–578 (2002).
120. Yang, H. *et al.* Subspecific origin and haplotype diversity in the laboratory mouse. *Nat. Genet.* **43**, 648–655 (2011).
121. Bennett, B. J. *et al.* Genetic architecture of atherosclerosis in mice: A systems genetics analysis of common inbred strains. *PLoS Genet.* **11**, e1005711 (2015).
122. Furlotte, N. A. *et al.* Increasing association mapping power and resolution in mouse genetic studies through the use of meta-analysis for structured populations. *Genetics* **191**, 959–967 (2012).
123. Geisert, E. E. *et al.* Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. *Mol. Vis.* **15**, 1730–1763 (2009).
124. Davis, R. C. *et al.* Genome-wide association mapping of blood cell traits in mice. *Mamm. Genome* **24**, 105–118 (2013).
125. Calabrese, G. *et al.* Systems genetic analysis of osteoblast-lineage cells. *PLoS Genet.* **8**, e1003150 (2012).
126. Ghazalpour, A. *et al.* Hybrid mouse diversity panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. *Mamm. Genome* **23**, 680–692 (2012).
127. Overall, R. W. *et al.* Genetics of the hippocampal transcriptome in mouse: a systematic survey and online neurogenomics resource. *Front. Neurosci.* **3**, 55 (2009).
128. Bubier, J. A. *et al.* Cross-Species Integrative Functional Genomics in GeneWeaver

- Reveals a Role for Pafah1b1 in Altered Response to Alcohol. *Front. Behav. Neurosci.* **10**, 1 (2016).
129. Repunte-Canonigo, V. *et al.* Nf1 regulates alcohol dependence-associated excessive drinking and gamma-aminobutyric acid release in the central amygdala in mice and is associated with alcohol dependence in humans. *Biol. Psychiatry* **77**, 870–879 (2015).
 130. Adkins, A. E. *et al.* Genomewide association study of alcohol dependence identifies risk loci altering ethanol-response behaviors in model organisms. *Alcohol. Clin. Exp. Res.* **41**, 911–928 (2017).
 131. Mozhui, K. *et al.* Genetic regulation of Nr1h3 expression: an integrative cross-species analysis of schizophrenia candidate genes. *Transl. Psychiatry* **1**, e25 (2011).
 132. Li, R., Svenson, K. L., Donahue, L. R. B., Peters, L. L. & Churchill, G. A. Relationships of dietary fat, body composition, and bone mineral density in inbred mouse strain panels. *Physiol. Genomics* **33**, 26–32 (2008).
 133. Ashbrook, D. G. & Hager, R. Empirical testing of hypotheses about the evolution of genomic imprinting in mammals. *Front. Neuroanat.* **7**, 6 (2013).
 134. Neuner, S. M., Heuer, S. E., Huentelman, M. J., O’Connell, K. M. S. & Kaczorowski, C. C. Harnessing Genetic Complexity to Enhance Translatability of Alzheimer’s Disease Mouse Models: A Path toward Precision Medicine. *Neuron* **101**, 399–411.e5 (2019).
 135. Cowin, R.-M. *et al.* Genetic background modulates behavioral impairments in

- R6/2 mice and suggests a role for dominant genetic modifiers in Huntington's disease pathogenesis. *Mamm. Genome* **23**, 367–377 (2012).
136. Sittig, L. J. *et al.* Genetic Background Limits Generalizability of Genotype-Phenotype Relationships. *Neuron* **91**, 1253–1259 (2016).
 137. Oakley, H. *et al.* Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* **26**, 10129–10140 (2006).
 138. Dickinson, M. E. *et al.* High-throughput discovery of novel developmental phenotypes. *Nature* **537**, 508–514 (2016).
 139. Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological architecture of adult human height. *Nat. Genet.* (2014).
doi:10.1038/ng.3097
 140. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421–427 (2014).
 141. Huan, T. *et al.* Integrative network analysis reveals molecular mechanisms of blood pressure regulation. *Mol. Syst. Biol.* **11**, 799 (2015).
 142. Valdar, W., Flint, J. & Mott, R. Simulating the collaborative cross: power of quantitative trait loci detection and mapping resolution in large sets of recombinant inbred strains of mice. *Genetics* **172**, 1783–1797 (2006).
 143. Morgan, A. P. & Welsh, C. E. Informatics resources for the Collaborative Cross and

related mouse populations. *Mamm. Genome* (2015). doi:10.1007/s00335-015-9581-z

144. *Systems Genetics*. **1488**, (Springer New York, 2017).
145. Churchill, G. a *et al.* The Collaborative Cross, a community resource for the genetic analysis of complex traits. *Nat. Genet.* **36**, 1133–1137 (2004).
146. Broman, K. W., Wu, H., Sen, S. & Churchill, G. A. R/qtl: QTL mapping in experimental crosses. *Bioinformatics* **19**, 889–890 (2003).
147. Carter-Falconer Mapping Function. in *Encyclopedia of Genetics, Genomics, Proteomics and Informatics* 276–276 (Springer Netherlands, 2008). doi:10.1007/978-1-4020-6754-9_2359
148. Haldane’s Mapping Function. in *Encyclopedia of Genetics, Genomics, Proteomics and Informatics* 836–836 (Springer Netherlands, 2008). doi:10.1007/978-1-4020-6754-9_7297
149. Kosambi’s Function. in *Encyclopedia of Genetics, Genomics, Proteomics and Informatics* 1066–1066 (Springer Netherlands). doi:10.1007/978-1-4020-6754-9_9098
150. Morgan. in *Encyclopedia of Genetics, Genomics, Proteomics and Informatics* 1255–1255 (Springer Netherlands, 2008). doi:10.1007/978-1-4020-6754-9_10747
151. Wang, J., Williams, R. W. & Manly, K. F. WebQTL: web-based complex trait analysis. *Neuroinformatics* **1**, 299–308 (2003).
152. Cleveland, W. S. Robust locally weighted regression and smoothing scatterplots. *J. Am. Stat. Assoc.* **74**, 829–836 (1979).

153. Falconer, D. S. & Mackay, T. F. C. *Introduction to Quantitative Genetics*. (Longman, 1996).
154. Miles, C. M. & Wayne, M. Quantitative trait locus (QTL) analysis. *Nat. Educ.* **1**, 208 (2008).
155. Haley, C. S. & Knott, S. A. A simple regression method for mapping quantitative trait loci in line crosses using flanking markers. *Heredity (Edinb)*. **69**, 315–324 (1992).
156. Zhou, X. & Stephens, M. Genome-wide efficient mixed-model analysis for association studies. *Nat. Genet.* **44**, 821–824 (2012).
157. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
158. Denny, J. C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* **26**, 1205–1210 (2010).

Supplementary files

Supplementary figure 1

.png

Production of each epoch of the BXD recombinant inbred family.

The BXDs up to BXD220 have been produced in 6 epochs, with epoch 1 being started in 1971. Red coloring has been used to represent regions of the genome coming from the inbred C57BL/6J (B6) parental strain, whereas white coloring has been used to represent regions of the genome coming from the inbred DBA/2J (D2) strain. Solid lines have been used to represent a single generation, whereas dashed lines represent several generations, with the number of generations written along the line. During the 1970s to 2001s strains that were at risk of going extinct were often backcrossed to B6 in an attempt to rescue them, and this is shown in the figure. During epochs 4-6, strains at risk of extinction were sometimes crossed to other BXD RI strains in an attempt to rescue them.

Beneath each epoch, the number of inbred strains begun, the number of strains with data within GeneNetwork, and the number of strains extant are shown. In cases where any crosses or backcrosses occurred these are also noted. Although the majority of the BXD family have the D2 Y-chromosome and B6 mitochondrial genome, this is not the case for all strains, and this is noted as well.

Adapted from (Nadeau and Auwerx, 2019; Peirce et al., 2004; Williams and Auwerx, 2015). Full details can be found in Supplementary file 2.

Supplementary table 1

.xlsx

Information on the nomenclature, availability, derivation and genotyping of all BXD strains (BXD1-BXD228).

Shows alternative names that have been used for BXD family members, details of when breeding was started, when production of these strains began at the Jackson Laboratory (JAX), the stock number and availability from JAX, the epoch, method of derivation, the origin of the mitochondrial genome, and platforms that each strain has been genotyped on, and the generation number if known.

Supplementary table 2

.xlsx

List of annotations in the BXD phenotype ontology used for our PheWAS study.

Shows the GeneNetwork trait ID, the 'Phenosome' (the numerical phenotype category), the phenotype category, the full phenotype description, the authors who produced the phenotype, the year of publication (or year of entry into GN if unpublished) and the PubMed ID (if published).

A: Standard F2 derived RI production

B: Advanced intercross derived RI production

A

Absolute Distance Between QTL Peak and Gene

B

Absolute Distance Between QTL Peak and Gene